Metalloproteinases and their Inhibitors under the Course of Immunostimulation by CPG-ODN and Specific Antigen Inhalation in Equine Asthma by Barton, Ann Kristin et al.
Research Article
Metalloproteinases and their Inhibitors under the Course of
Immunostimulation by CPG-ODN and Specific Antigen
Inhalation in Equine Asthma
Ann Kristin Barton ,1 Tarek Shety,1,2 John Klier,3 Sabine Geis,1,3 Ralf Einspanier,4
and Heidrun Gehlen1
1Equine Clinic, Freie Universitaet Berlin, Germany
2Animal Medicine Department, Faculty of Veterinary Medicine, Zagazig University, Zagazig, Egypt
3Centre for Clinical Veterinary Medicine, Equine Clinic, LMU Munich, Germany
4Institute of Veterinary Biochemistry, Freie Universitaet Berlin, Germany
Correspondence should be addressed to Ann Kristin Barton; ann-kristin.barton@fu-berlin.de
Received 7 January 2019; Revised 4 April 2019; Accepted 2 May 2019; Published 17 June 2019
Academic Editor: Tânia Silvia Fröde
Copyright © 2019 Ann Kristin Barton et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Objectives. Inhalation of immunostimulatory bacterial DNA segments (cytosine-phosphate-guanosine-oligodeoxynucleotides,
CpG-ODN) normalizes clinical and cytologic parameters in severe equine asthma. We hypothesized that CpG-ODN inhalation
also reduces the misbalance of elastinolytic activity in asthmatic horses. Methods. Twenty asthmatic horses diagnosed by clinical
examinations using a scoring system were included. All horses inhaled CpG-ODNs for 14 days in 2-day intervals. Matrix
metalloproteinase (MMP-2/-9) and tissue inhibitors of metalloproteinase (TIMP-1/-2) concentrations were measured in tracheal
aspirates using equine sandwich ELISAs before and 2 and 6 weeks after CpG-ODN inhalation. Results. MMP and TIMP
concentrations correlated with the results of clinical scoring in all stages of equine asthma. Inhalation therapy led to signiﬁcant
reductions in clinical scores. MMP-2, MMP-9, and TIMP-2 concentrations were signiﬁcantly reduced immediately, and all
MMP and TIMP concentrations 6 weeks after therapy. Discussion. In equine asthma, overexpression of MMPs contributes to
pathological tissue destruction, while TIMPs counteract MMPs with overexpression leading to ﬁbrosis formation. The results
of this study show that CpG-ODN inhalation may be an eﬀective therapy to address a misbalance in equine asthma.
Conclusions. Misbalance of elastinolytic activity seems to improve by CpG-ODN inhalation for at least 6 weeks posttherapy,
which may reduce the remodeling of the extracellular matrix. Further studies should evaluate this eﬀect in comparison to
glucocorticoid inhalation therapy. Signiﬁcance. CpG-ODN inhalation may be an eﬀective therapy in the prevention of
pulmonary ﬁbrosis formation in equine asthma.
1. Introduction
Although environmental dust reduction remains the cor-
nerstone in equine asthma therapy [1], drug therapy may
also be indicated, both in situations where the implementa-
tion of appropriate environmental changes is problematic
and in horses with severe clinical disease, as a necessary
adjunct to the implementation of optimal environmental
changes. Unfortunately, despite glucocorticoids and bron-
chodilators suppressing the inﬂammatory response and
ameliorating clinical signs of bronchial obstruction, they are
not curative. A new therapeutic causative approach for
equine asthma is inhalation of gelatinase particle bound
cytosine-phosphate-guanosine-oligodeoxynucleotides (CpG-
ODN) as described by Klier et al. [2–5]. The CpG motive, a
distinct sequence of nucleotides appearing recurrently in bac-
terial and viral DNA, contains a central cytosine-phosphate-
guanosine-dinucleotide. These CpG sequences are common
in prokaryotic DNA but are rare and commonly sup-
pressed in mammalian DNA. In addition, they are usually
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methylated in mammals, while they are unmethylated in
viral and bacterial DNA. These unmethylated CpG motives
are recognized as danger signals in many species explaining
their immune-stimulatory eﬀect. Within the cell, the
unmethylated DNA motives are recognized as pathogen-
associated molecular patterns (PAMPs) by the intracellular
toll-like receptor 9 (TLR 9) and lead to a strong Th1
immune response, which would be appropriate for a viral,
bacterial, or parasite infection [6, 7]. In the case of equine
asthma, this leads to an immune shift from a Th2 to a Th1
reaction, suppression of IL-4, increase in IL-10 and
IFN-gamma, and a cytological reduction in neutrophils
in respiratory secretions [2, 3]. In several studies, the
authors could show an improvement in clinical signs, respi-
ratory secretion cytology, and arterial blood gas analysis in
horses suﬀering from severe equine asthma.
Remodeling of the extracellular matrix (ECM) of pulmo-
nary connective tissue is a continuous process allowing
growth and regeneration. To allow for healing, growth,
and maintenance of tissue stability, a balance exists
between degradation. Zinc-dependent endopeptidases, so-
called matrix metalloproteinases (MMPs), are the most
important proteolytic enzymes, and resynthesis of extracellu-
lar matrix structures in healthy subjects [8]. Several studies
have demonstrated a central role of MMPs in chronic respi-
ratory disease in human asthma and COPD as well as equine
asthma [9–13]. In the airways of asthmatic patients, activated
ﬁbroblasts account for an excessive matrix production. This
bronchial remodeling is also seen in equine asthma [14].
An imbalance between diﬀerent MMPs, particularly
MMP-9, and their tissue inhibitors (TIMPs), particularly
TIMP-1, which is the most widely distributed and acts
on all active MMPs, has been shown in several studies.
Increased levels of MMP-9 [15, 16] and also MMP-2
[17, 18] as well as elevated TIMP-1 and TIMP-2 levels
are found in the airways of asthmatic patients [15, 17–19].
This suggests that pathological airway remodeling in asthma,
resulting in airway ﬁbrosis, may be a consequence of overre-
pair mechanisms. MMPs degrade the ECM directly, but this
may counteract ﬁbrosis formation [20]. However, an exces-
sive degradation over a longer period of time may also result
in a feedback of overrepair cycles, leading to increased
synthesis and deposition of ECM [21].
In former studies of our group, we could show a
misbalance in elastinolytic and collagenolytic activity in
equine asthma, which may contribute to ﬁbrosis formation
in long-term disease [13, 22]. Increased concentrations of
MMPs and TIMPs were found in bronchoalveolar lavage
ﬂuid (BALF) of asthmatic horses suﬀering from mild-to-
moderate as well as severe disease.
As the complex inﬂammatory processes in equine asthma
have been studied intensely, but are still not fully understood
[1, 23], we hypothesized that CpG-ODN inhalation might
also aﬀect the elastinolytic processes within the ECM
contributing to bronchial remodeling and that pulmonary
ﬁbrosis formation might be inhibited by inhalation of CpG-
ODN as a consequence of a downregulation of the underly-
ing allergic inﬂammation. The objectives of the present study
were to compare the concentrations of MMP-2 and MMP-9
as well as TIMP-1 and TIMP-2 in tracheal aspirate (TA) with
clinical ﬁndings and cytology results under the course of
CpG-ODN inhalation.
2. Material and Methods
In the present study, 10 horses inhaled CpG-ODN and 10
horses inhaled CpG-ODN in addition to speciﬁc allergens;
samples were obtained from a prior study by our group [2].
As the addition of speciﬁc allergens did not have an impact
on the eﬀect of CpG-ODN inhalation, we included all
samples as a study population to increase the statistical
power concerning the diﬀerences in MMP and TIMP con-
centrations in tracheal wash samples at three time points,
before and 2 weeks and 6 weeks after inhalation therapy.
2.1. Preparticipation Examination. A total of 20 horses of
mixed breeds were presented for participation in this pro-
spective clinical trial with a history of equine asthma. The
study was approved by the regional legal agency for animal
experiments of the Government of Upper Bavaria, Germany
(No. 55.2-1-54-2531-31-10). The owners gave permission to
involve their horses in the study. The preparticipation exam-
ination included respiratory rate at rest, breathing type,
auscultation of the trachea and both lung ﬁelds, endoscopy
and cytology of tracheal aspirates, arterial blood gas analysis,
and intrapleural pressure measurement. Inclusion criteria
were tachypnea (>16/min), increased abdominal eﬀort in
expiration, neutrophilia >25% in cytology, hypoxia at rest
(partial oxygen pressure< 90mmHg), and increased intra-
pleural pressure (>15 cm H2O). Results were included in a
scoring system modiﬁed from prior studies [24] as shown
in Table 1 to classify the horses as mildly, moderately, or
severely asthmatic.
All examinations and inhalation therapy took place at the
horses’ customary stables. During the study period, no
changes in the management of the horses were implemented.
In addition, none of the horses had received any additional
medications for at least 8 weeks before the start and
throughout the duration of the study.
2.2. CpG-ODN Inhalation. Nanoparticles were produced
and loaded with CpG-ODN 2216 (Biomers GmbH, Ulm,
Germany) as previously described [2, 3]. Each inhalation
utilized 187.5μg CpG-ODN, bound to 3.75mg GNP and dis-
persed in 2.5ml highly puriﬁed water (HPW), with a ﬁnal
concentration of 1.5mg/ml GNP and 0.075mg/ml CpG-
ODN. The inhalation regimen was conducted with Equine
Haler®™ (Equine HealthCare Aps, Hoersholm, Denmark)
and Aeroneb® Go micropump nebulizer (Aerogen, Galway,
Ireland) as previously described [2, 3]. The seven inhalations
in each horse were administered every other day.
2.3. Clinical Scoring and Clinical Pathology. The ﬁrst evalua-
tion of the horses occurred before the treatment (t0) and
included clinical evaluation, bronchoscopy, and evaluation
of pulmonary function parameters, as well as cytological,
immunological, and laboratory-chemical parameters. The
second evaluation (t1) occurred after the completion of the
seventh inhalation 2 weeks later. The third evaluation (t2)
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occurred 6 weeks after the last treatment, in order to
determine any long-term eﬀect.
2.4. Laboratory Analysis of Interleukins, MMPs, and TIMPs.
Venous blood samples taken from the jugular vein and
20ml of tracheal wash ﬂuid were centrifuged, and the super-
natant was immediately frozen using liquid nitrogen and
stored at −80°C until assayed. Protein concentrations were
measured and used for normalization. Concentrations of
the cytokines IL-4, IL-10, IL-17, and IFN-γ were measured
in tracheal wash ﬂuid, using equine sandwich ELISAs
(Equine IL-4 kit, Equine IL-10 kit, Equine IL-17 kit, and
Equine IFN-γ kit; R&D Systems, Minneapolis, USA) found
to be reliable in prior studies by our group [5] and following
the manufacturer’s protocol. MMP-2 and MMP-9 as well as
TIMP-1 and TIMP-2 were also measured in BALF using
sandwich ELISAs (Equine MMP-2 kit, Equine MMP-9 kit,
Equine TIMP-1 kit, and Equine TIMP-2 kit; USCN Life
Science Inc., China) used in former studies by our group
[13, 22]. MMP and TIMP concentrations were not evaluated
in serum, as previous studies had shown no signiﬁcant
changes in diﬀerent stages of equine asthma (data not pub-
lished). For all parameters evaluated, standards and samples
were set up in duplicates and the absorbance was measured
with an ELISA microplate reader at 450 nm immediately.
2.5. Statistics. Data were statistically analyzed using SPSS and
were expressed as mean ± standard deviation (SD). The data
were tested for normal distribution using the Shapiro-Wilk
Test. While some data were found to be normally distributed,
other was found not to, so we preferred nonparametric
tests for the whole data. The level of signiﬁcance was set
at P < 0 05. The Kruskal-Wallis H test was used to compare
between the severities of diﬀerent disease group (mild, mod-
erate, and severe equine asthma) followed by post hoc testing
using the Mann–WhitneyU test for a 2-group comparison to
determine intergroup diﬀerences. Correlations between
neutrophil percentages and the concentrations of MMP-2,
MMP-9, TIMP-1, and TIMP-2 were calculated using the
Spearman correlation test.
3. Results
The results of the clinical examinations and interleukin
measurements have been published in a former paper [2].
They are summarized here to allow the later discussion in
correlation to MMPs and TIMPs.
Table 1: Clinical score modiﬁed from Barton et al. [24].
Score Max. points
(1) Cough induction
No cough after manual compression of larynx 0
1
Coughing during manual larynx compression 1
Very frequent coughing 1
Spontaneous coughing 1
(2) Dyspnoea at rest
Prolonged expiration 1
3
Increased abdominal eﬀort in expiration 1













Signiﬁcantly increased secretions with moderate viscosity 1
2Highly increased secretions with high viscosity 2
Thickened carina of the trachea 1










≤6 points: mild asthma, 6-10 points: moderate asthma, 11-15 points: severe asthma.
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3.1. Clinical Scoring. In all 20 horses presented for participa-
tion in this study with a history of equine asthma, the disease
was conﬁrmed. Animals were classiﬁed as mild (n = 4),
moderate (n = 11), or severe equine asthma (n = 5) at the
beginning of the study. As described in the former paper,
scores for respiratory rate, breathing type, auscultation, nasal
discharge, AaDO2, PaO2, amount, and viscosity of respira-
tory secretions were all reduced signiﬁcantly 6 weeks after
CpG-ODN inhalation therapy [2]. The latest three were
already reduced signiﬁcantly after 2 weeks.
3.2. Interferon-γ, Interleukin-4, Interleukin-10, and
Interleukin-17. As described by Klier et al. [2], IL-4 concen-
tration showed a signiﬁcant decrease in tracheal wash ﬂuid
2 and 6 weeks after the end of CPG-ODN inhalation therapy
and in serum after 6 weeks. Concentrations of IL-10 and
IL-17 did not decrease, neither in tracheal wash (IL-10
and IL-17) nor in serum (IL-10). IFN-γ concentration was
reduced after 2 and 6 weeks in serum, while no decrease
was found for tracheal wash [2].
3.3. MMP-2 Elisa. Signiﬁcant increases in MMP-2 concentra-
tion in tracheal wash were found between diﬀerent severity
grades of equine asthma rising from 14 0 ± 0 2 ng/ml in
mildly to 18 4 ± 0 3 ng/ml in severely aﬀected horses. Under
CpG-ODN inhalation therapy, overall MMP-2 concentra-
tion decreased from 15 9 ± 0 5 ng/mg (before therapy), over
14 6 ± 0 3 ng/ml (2 weeks after therapy), to 13 0 ± 0 3 ng/ml
(6 weeks after therapy). This decrease was signiﬁcant 2 weeks
after therapy.
3.4. MMP-9 Elisa. More obvious diﬀerences between disease
severity groups were detected for MMP-9 in tracheal wash
rising from 280 2 ± 94 0 in mildly to 933 8 ± 20 0 pg/ml in
severely asthmatic horses. Under CpG-ODN inhalation
therapy, overall MMP-9 concentration decreased from
606 9 ± 85 5 pg/mg (before therapy), over 324 8 ± 81 7 pg/ml
(2 weeks after therapy), to 210 6 ± 38 4 pg/ml (6 weeks after
therapy). This decrease was signiﬁcant 6 weeks after therapy.
3.5. TIMP-1 Elisa. Signiﬁcant increases in tracheal wash con-
centration between diﬀerent severity grades of equine asthma
were found for TIMP-1 rising from 93 6 ± 12 6 ng/ml in
mildly to 179 7 ± 6 4 ng/ml in severely aﬀected horses. Under
CpG-ODN inhalation therapy, overall TIMP-1 concentra-
tion decreased from 139 4 ± 11 3 ng/mg (before therapy),
over 115 4 ± 15 9 ng/ml (2 weeks after therapy), to 88 4 ±
16 9 ng/ml (6 weeks after therapy). This decrease was
signiﬁcant 6 weeks after therapy.
3.6. TIMP-2 Elisa. Signiﬁcant increases in tracheal wash
TIMP-2 concentration between diﬀerent severity grades of
equine asthma were found rising from 99 3 ± 13 8 ng/ml
in mildly to 169 5 ± 6 8 ng/ml in severely aﬀected horses.
Under CpG-ODN inhalation therapy, overall TIMP-2
concentration decreased from 124 6 ± 10 6 ng/mg (before
therapy), over 77 6 ± 5 3 ng/ml (2 weeks after therapy),
to 70 1 ± 6 3 ng/ml (6 weeks after therapy). This decrease
was signiﬁcant 2 weeks after therapy.
Spearman correlation test showed that there were
positive correlation of neutrophils’ percentages in tracheal
wash cytology with MMP-2 and MMP-9 concentrations
(r = 0 612 and r = 0 651, respectively) and the correlation
was signiﬁcant at P < 0 05. There were also positive correla-
tions of neutrophils’ percentages with TIMP-1 and TIMP-2
concentrations (r = 0 708 and r = 0 667, respectively), and
the correlation was signiﬁcant at P < 0 01.
Overall, CPG-ODN inhalation therapy led to signiﬁ-
cant reductions in clinical scores; concentrations of IL-4,
MMP-2, MMP-9, and TIMP-2 in tracheal wash decreased
after 2 weeks, and all MMP and TIMP concentrations 6
weeks after therapy. A concluding summary of all MMP
and TIMP measurements is presented in Tables 2 and 3.
4. Discussion
To our knowledge, this is the ﬁrst study to show that the
misbalance of elastinolytic activity of the extracellular matrix
in equine asthma might be positively inﬂuenced by CpG-
ODN inhalation for at least 6 weeks posttherapy. If this is
actually the case, the remodeling of the extracellular matrix
and ﬁbrosis formation might be reduced in this common
disease. In human asthma, the degree of MMP activity can
be linked to the intensity of the inﬂammatory processes in
the airways. The MMP/TIMP balance or rather disbalance
is widely accepted to have a role in the pathogenesis of air-
ﬂow limitation and reﬂect the extent of structural changes
in the lung [20, 25, 26].
Table 2: Concentrations of MMP-2, MMP-9, TIMP-1, and TIMP-2 in tracheal aspirates from horses suﬀering from equine asthma of
diﬀerent disease severity (mild, moderate, and severe).
Mild asthma (n = 4) Moderate asthma (n = 11) Severe asthma (n = 5)
MMP-2 (ng/ml)
14 0 ± 0 2
14.05 (13.5 - 14.4)
15 6 ± 0 2∗
15.43 (15.1 - 16.7)
18 4 ± 0 3∗
18.38 (17.9 - 19.1)
MMP-9 (pg/ml)
280 2 ± 94 1
271.89 (107.3 - 469.7)
535 6 ± 104 8
536.97 (178.5 - 819.1)
933 8 ± 20 0∗
916.77 (908.3 - 993.2)
TIMP-1 (ng/ml)
93 6 ± 12 6
104.81 (56.0 – 108.7)
144 5 ± 9 3∗
152.36 (103.3 – 163.1)
179 7 ± 6 4∗
181.45 (165.0 – 191.0)
TIMP-2 (ng/ml)
99 3 ± 13 8
101.07 (65.6 - 129.4)
102 2 ± 11 9
104.22 (68.2 - 137.1)
169 5 ± 6 7∗
165.99 (157.3 - 188.8)
The results are expressed as mean ± SE, median, and range. The statistical analysis was performed by the Kruskal-Wallis H test, and ∗ indicates signiﬁcant
diﬀerences between diﬀerent severity groups.
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In severe equine asthma, increased MMP-2 and MMP-9
levels were shown using gelatin zymography [9]. Particularly,
MMP-9 levels were clearly upregulated in diﬀerent stages of
equine asthma [13]. Both MMP-2 and MMP-9 showed a
correlation to stable dust concentrations [27–29]. MMP-9
levels decreased with BALF neutrophilia under budesonide,
an inhalative glucocorticoid [22]. This was not the case for
MMP-2, which seems to be more of a housekeeping enzyme
[10]. Other authors also showed increased activities of
elastinolytic MMP-9 and MMP-13 as well as collagenolytic
MMP-8 in equine asthma [11, 12].
Tissue inhibitors of metalloproteinases (TIMPs) are
natural antagonists of MMPs [30, 31]. In human COPD,
MMP-9 and TIMP-1 concentrations in BALF increased,
which was not the case in plasma [32]. TIMP-1 and
TIMP-2 concentrations as well as MMP-TIMP ratios have
also been studied in equine asthma [13] showing increased
levels of TIMPs in mild-to-moderate as well as severe
equine asthma compared to controls and normalization
of MMP-TIMP ratios under budesonide therapy [22].
In unison with former studies, MMP-2/-9 and TIMP-1/-2
levels increased with severity of equine asthma and all
MMPs/TIMP concentrations decreased with clinical score
parameters within 2-6 weeks after CPG-ODN inhalation.
Interestingly, this eﬀect was not yet found at t1 (2 weeks
postinhalation), but at t2 (6 weeks post inhalation) for
MMP-9 and TIMP-1, which are probably the most impor-
tant enzymes in natural disease. This shows that CpG-
ODN does not only have a long-term eﬀect, but that therapy
of extracellular remodeling may even require longer terms
of treatment. This theory should be substantiated by longi-
tudinal studies including lung tissue biopsies to look at
ﬁbrosis formation in long-term disease. A possible long-
term eﬀect should be further evaluated and tried to be
extended, possibly by increasing the numbers of inhala-
tions, increasing the time-span of inhalation intervals or
repetition of inhalation therapy after some weeks or even
months. Remodeling of the ECM and ﬁbrosis formation is
a very slow process in human and equine asthma; therefore,
models of long-term therapy should be developed.
The observed positive eﬀect of CpG-ODN inhalation
therapy on clinical parameters and cytology of respiratory
secretions has been conﬁrmed in several in vitro and
in vivo studies for equine asthma and could be shown to last
at least 6 weeks [2–5, 33]. All clinical studies were ﬁeld
studies; therefore, the combined eﬀect of CpG inhalation
and a low-dust environment remains to be studied. It is well
known that clinical parameters, cytology, and lung function
after common pharmacological therapy in equine asthma
including systemic or inhalative glucocorticoid therapy,
secretolytics, and bronchodilators improve much better
under adjacent measures to reduce the allergen and dust-
particle load in the environment [1, 14, 23]. In this study,
horses were kept in their home stables in diﬀerent environ-
ments and no environmental changes were implemented
throughout the study. All included subjects had clinical and
cytological evidence of airway obstruction and inﬂammation,
showing they were not in disease remission. On the other
hand, this allows for a better evaluation under natural condi-
tions of the eﬀect of CpG-ODNs on the elastinolytic activity,
as implementation of a low-dust environment may have also
led to decreasing inﬂammation and MMP/TIMP concentra-
tions in tracheal aspirates. Nevertheless, further studies
should include a control group inhaling placebo to study
the eﬀect of seasonal changes on elastinolytic activity.
Although reference values of MMP and TIMP concentra-
tions have only been described in BALF in healthy controls
[13], we assume that MMP and TIMP levels in tracheal wash
samples were elevated, as former studies have shown a strong
correlation between their concentrations in BALF and
clinical and cytological parameters. Nevertheless, the authors
suggest that further prospective studies should rather use
BALF, as proposed by current literature for the diagnoses of
all stages of equine asthma and used in prior studies on
MMP/TIMP misbalance.
The relation between clinical improvement and decreas-
ing MMP/TIMP levels under CpG-ODN inhalation might
not be directly causative but reﬂect the degree of decreasing
airway inﬂammation and achievement of disease remission.
The direct mechanism, by which CpG-ODN inhalation
positively inﬂuences the misbalance in elastinolytic activity
in equine asthma, needs further studies. Former studies have
shown that several interleukins (IL-4, IL-10, and IFN-γ) may
have to be considered, as their levels changed in accordance
with the Th2/Th-1shift [3, 5], and in this study, a decrease
was also found, at least for IL-4 (serum and tracheal wash)
and IFN-γ (serum). A downregulation of the Th2 immune
response and thus the IL-4 secretion is expected by the
agonistic activity of CpG-ODNs on the intracellular TLR9
[2, 34, 35]. Decreasing INF-γ concentrations in serum over
6 weeks show a long-lasting anti-inﬂammatory eﬀect of
CpG-ODN inhalation as well [36–38]. The high positive
correlations of MMPs and neutrophil percentages in BALF
suggest these cells to be the origin of MMPs, in particular
MMP-9, in equine asthma with neutrophils being one of
the most important sources of MMPs [13]. This is supported
by the high correlations betweenMMP and TIMP concentra-
tions and neutrophil percentages in tracheal aspirate cytology
in the presented study. On the other hand, IL-4 and INF-γ
concentrations also correlate with decreasing airway neu-
trophilia [2], which may be possible cross-links, but as
equine asthma pathophysiology is so complex, further
mechanisms may contribute to the positive inﬂuence of
Table 3: Concentrations of MMP-2, MMP-9, TIMP-1, and TIMP-2
in tracheal aspirates from 20 asthmatic horses measured on
admission (t0), 2 weeks (t1), and 6 weeks (t2) after CpG-ODN
inhalation.
t0 t1 t2
MMP-2 (ng/ml) 15 9 ± 0 5 14 6 ± 0 3∗ 13 0 ± 0 3∗
MMP-9 (pg/ml) 606 9 ± 85 5 324 8 ± 81 7 210 6 ± 38 4∗
TIMP-1 (ng/ml) 139 4 ± 11 3 115 4 ± 15 9 88 4 ± 16 9∗
TIMP-2 (ng/ml) 124 6 ± 10 6 77 6 ± 5 3∗ 70 1 ± 6 3∗
The results are expressed as mean ± SE (min.-max.). ∗ marks a signiﬁcant
reduction of MMP/TIMP concentration in comparison to t0.
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CpG-ODNs on elastinolytic activity and remodeling of the
extracellular matrix.
In conclusion, this study shows further positive eﬀects of
CpG-ODN inhalation in equine asthma possibly improving
the elastinolytic activity for at least several weeks, which
may reduce the remodeling of the extracellular matrix.
Further studies should evaluate this eﬀect in comparison
to glucocorticoid inhalation therapy and with adjacent
improvement of the environment in terms of allergen
and dust-particle load.
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